Does cannabis help inflammatory bowel disease? What a June 2026 systematic review of THC actually found

It is one of the questions our community asks most often, and one of the hardest to answer honestly: does cannabis actually help IBD, or does it just take the edge off?

A lot of people are not waiting for a tidy answer. According to the Crohn's & Colitis Foundation, surveys in the United States and Canada have found that roughly 15–20% of people with IBD currently use cannabis, and up to 40% have tried it at some point to ease symptoms. That is a large share of the community making a personal decision largely in the absence of clear evidence.

A systematic review published in June 2026 set out to pull that evidence together. It is worth reading carefully — not because it settles the debate, but because it is honest about how much we still do not know.

What the Foundation's position already was

Before the new review, the starting point from patient organisations was already cautious. The Crohn's & Colitis Foundation states plainly that there is currently no evidence that medical cannabis can reduce IBD inflammation or improve disease activity. Cannabis, the Foundation notes, may improve some symptoms — abdominal pain is the one most often cited — but that is a different thing from changing the underlying inflammatory process that drives the disease and the damage it does to the bowel.

That distinction — feeling better versus the disease actually being better — runs through the whole topic, and it is exactly what the new review tried to measure.

How the review was built

In June 2026, the Journal of Cannabis Research published a systematic review by Jugl and colleagues assessing the effectiveness of THC-containing cannabis in IBD. The methods are the part to pay attention to: the review followed the Cochrane Handbook, reported to PRISMA standards, and used the GRADE framework to rate how much confidence each finding deserves. Those are the markers of a review trying to be rigorous rather than promotional.

The authors found eight studies in total — four randomised controlled trials and four non-interventional (observational) studies. (Jugl et al., J Cannabis Res, June 2026)

Here the first caution appears. The four observational studies were judged to be at serious or critical risk of bias, so they were excluded from the formal evidence ratings altogether. And the four randomised trials — normally the strongest study design — were all judged to be at high risk of bias. In other words, even the best available evidence on this question is shakier than we would like. (Jugl et al., 2026)

What it found on the disease itself

On the measures that tell you whether the disease is actually under control, the review found nothing:

• Clinical remission — no effect (pooled across 3 trials, 150 participants)
• Endoscopic scores — no effect (2 trials, 88 participants)
• Nausea — no effect (56 participants)

Endoscopic scores matter here because they are a direct look at whether the bowel lining is healing, rather than a report of how someone feels. On that front-line measure of healing, the THC trials showed no benefit. (Jugl et al., 2026)

What it found on symptoms

The symptom picture was more mixed, and this is probably where the honest nuance lives.

The review found low-certainty evidence of improvement in two things: bloating and appetite (each based on a single trial of 56 participants). For several other symptom measures, the results were genuinely mixed and the review could not draw a conclusion either way:

• Clinical disease activity — inconclusive (4 trials, 180 participants)
• Bowel-movement frequency — inconclusive (3 trials, 148 participants)
• Quality of life — inconclusive (3 trials, 122 participants)
• Pain — inconclusive (2 trials, 88 participants)

Across all of these outcomes, the certainty of the evidence was rated only low to moderate. A "low-certainty" signal is not nothing — but it is a long way from "this works." (Jugl et al., 2026)

What the authors concluded

The review's bottom line is deliberately undramatic: the current evidence on THC-containing cannabis for IBD is inconclusive. The findings are heterogeneous — meaning the studies point in different directions — and the certainty is predominantly low to moderate. The authors were careful to frame this as a gap rather than a verdict: they did not find that cannabis treats IBD, and they did not find that it is useless. They found that the studies done so far are not strong enough, consistent enough, or large enough to answer the question, and that this uncertainty is striking given how many people are already using it. (Jugl et al., 2026)

What this means for our community

If you use cannabis, or are thinking about it, the most useful takeaway is probably the gap between symptom relief and disease control. The best current evidence does not support cannabis as a way to calm IBD inflammation, induce remission, or heal the bowel lining — and the Foundation is explicit that there is no evidence it does those things. What some people may get is a degree of symptom relief, and even that rests on low-certainty evidence so far.

That gap matters practically: feeling better is not the same as the inflammation being controlled, and relying on symptom relief alone can mask disease activity that still needs treating. Cannabis can also interact with other medications and carries its own risks and legal considerations that vary a great deal by where you live.

None of that is a reason for shame or secrecy — it is a reason to keep your IBD team in the loop. If cannabis is part of your life, or you are curious about it, tell the clinicians managing your care so it can be weighed alongside your prescribed treatment, not instead of it.

Your clinician knows your case best — ask them first.

---